RNS Number : 2898M
Redx Pharma plc
29 April 2024

REDX PHARMA PLC

("Redx" or the "Company")

Update on AIM Delisting

Alderley Park, UK, 29 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today provides a further update with respect to the cancellation of the admission of its ordinary shares of 1 pence each (the "**Ordinary Shares**") to trading on AIM (the "**AIM Delisting**"), as originally announced on 2 April 2024.

As previously announced, the last day of trading in the Ordinary Shares on AIM will be 30 April 2024 and the AIM Delisting will become effective at 7:00 a.m. on 1 May 2024. Details of the matched bargain facility to be provided by J P Jenkins to assist shareholders wishing to trade in Ordinary Shares following the AIM Delisting will be available on the Company's website [www.redxpharma.com.](www.redxpharma.com) The matched bargain facility will be effective from 7:30 a.m. on 1 May 2024.

Following the AIM Delisting, SPARK Advisory Partners Limited will cease to act as nominated adviser and Panmure Gordon (UK) Limited will cease to act as broker to the Company.

For further information, please contact:

Redx Pharma Plc   T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com

SPARK Advisory Partners (Nominated Adviser)   T: +44 (0)203 368 3550
Matt Davis/Adam Dawes

Panmure Gordon (UK) Limited (Broker)   T: +44 (0)207 886 2500
Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting   T: +44 (0)203 727 1000
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a

targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.

END

STRPPUQGCUPCGQQ